Skip to content
MRD Watch

Wednesday, November 18, 2026

Subscribe
Sponsor this briefing. One site and newsletter slot, $250/week.

Briefing

ASCO GU 2026 proof-of-concept series links ctDNA to disease status in marker-negative germ cell tumors

An ASCO GU 2026 proof-of-concept series of 33 ctDNA samples from 21 patients with germ cell tumors, most of them marker-negative, reported 100% concordance between ctDNA detection and radiologic or pathologic disease status across the treatment phases assessed.

Journal of Clinical Oncology